Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes.
Alzheimer’s diseases
COVID-19
Diabetes mellitus
Docking
LPAR
Lupron
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Feb 2024
21 Feb 2024
Historique:
received:
15
09
2023
accepted:
19
02
2024
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
22
2
2024
Statut:
epublish
Résumé
The COVID-19 pandemic caused by the SARS-CoV-2 virus has greatly affected global health. Emerging evidence suggests a complex interplay between Alzheimer's disease (AD), diabetes (DM), and COVID-19. Given COVID-19's involvement in the increased risk of other diseases, there is an urgent need to identify novel targets and drugs to combat these interconnected health challenges. Lysophosphatidic acid receptors (LPARs), belonging to the G protein-coupled receptor family, have been implicated in various pathological conditions, including inflammation. In this regard, the study aimed to investigate the involvement of LPARs (specifically LPAR1, 3, 6) in the tri-directional relationship between AD, DM, and COVID-19 through network analysis, as well as explore the therapeutic potential of selected anti-AD, anti-DM drugs as LPAR, SPIKE antagonists. We used the Coremine Medical database to identify genes related to DM, AD, and COVID-19. Furthermore, STRING analysis was used to identify the interacting partners of LPAR1, LPAR3, and LPAR6. Additionally, a literature search revealed 78 drugs on the market or in clinical studies that were used for treating either AD or DM. We carried out docking analysis of these drugs against the LPAR1, LPAR3, and LPAR6. Furthermore, we modeled the LPAR1, LPAR3, and LPAR6 in a complex with the COVID-19 spike protein and performed a docking study of selected drugs with the LPAR-Spike complex. The analysis revealed 177 common genes implicated in AD, DM, and COVID-19. Protein-protein docking analysis demonstrated that LPAR (1,3 & 6) efficiently binds with the viral SPIKE protein, suggesting them as targets for viral infection. Furthermore, docking analysis of the anti-AD and anti-DM drugs against LPARs, SPIKE protein, and the LPARs-SPIKE complex revealed promising candidates, including lupron, neflamapimod, and nilotinib, stating the importance of drug repurposing in the drug discovery process. These drugs exhibited the ability to bind and inhibit the LPAR receptor activity and the SPIKE protein and interfere with LPAR-SPIKE protein interaction. Through a combined network and targeted-based therapeutic intervention approach, this study has identified several drugs that could be repurposed for treating COVID-19 due to their expected interference with LPAR(1, 3, and 6) and spike protein complexes. In addition, it can also be hypothesized that the co-administration of these identified drugs during COVID-19 infection may not only help mitigate the impact of the virus but also potentially contribute to the prevention or management of post-COVID complications related to AD and DM.
Identifiants
pubmed: 38383841
doi: 10.1038/s41598-024-55013-9
pii: 10.1038/s41598-024-55013-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4328Subventions
Organisme : New Teacher Development Scholarship, Chulalongkorn University
ID : DNS_66_076_3700_008
Informations de copyright
© 2024. The Author(s).
Références
Wang, R., Chen, J. & Wei, G.-W. Mechanisms of SARS-CoV-2 evolution revealing vaccine-resistant mutations in Europe and America. J. Phys. Chem. Lett. 12, 11850–11857 (2021).
pubmed: 34873910
pmcid: 8672435
doi: 10.1021/acs.jpclett.1c03380
Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361–379 (2023).
pubmed: 37020110
doi: 10.1038/s41579-023-00878-2
Moghadasi, S. A. et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci. Adv. 9, eade8778 (2023).
pubmed: 36989354
pmcid: 10058310
doi: 10.1126/sciadv.ade8778
Gómez, S. A. et al. Binding of SARS-CoV-2 to cell receptors: A tale of molecular evolution. Chembiochem 22, 724–732 (2021).
pubmed: 32986926
doi: 10.1002/cbic.202000618
Xiang, H., Lu, Y., Shao, M. & Wu, T. Lysophosphatidic acid receptors: Biochemical and clinical implications in different diseases. J. Cancer 11, 3519–3535 (2021).
doi: 10.7150/jca.41841
Geraldo, L. H. M. et al. Role of lysophosphatidic acid and its receptors in health and disease: Novel therapeutic strategies. Signal Transduct. Target Ther. 6, 45 (2021).
pubmed: 33526777
pmcid: 7851145
doi: 10.1038/s41392-020-00367-5
Zhao, Y. & Natarajan, V. Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling. Biochim. Biophys. Acta 1831, 86–92 (2013).
pubmed: 22809994
doi: 10.1016/j.bbalip.2012.06.014
Yung, Y. C., Stoddard, N. C., Mirendil, H. & Chun, J. Lysophosphatidic acid signaling in the nervous system. Neuron 85, 669–682 (2015).
pubmed: 25695267
pmcid: 4400838
doi: 10.1016/j.neuron.2015.01.009
McDonald, W. S. et al. Altered cleavage plane orientation with increased genomic aneuploidy produced by receptor-mediated lysophosphatidic acid (LPA) signaling in mouse cerebral cortical neural progenitor cells. Mol. Brain 13, 169 (2020).
pubmed: 33317583
pmcid: 7734743
doi: 10.1186/s13041-020-00709-y
García-Díaz, B. et al. Loss of lysophosphatidic acid receptor LPA(1) alters oligodendrocyte differentiation and myelination in the mouse cerebral cortex. Brain Struct. Funct. 220, 3701–3720 (2015).
pubmed: 25226845
doi: 10.1007/s00429-014-0885-7
Dawson, J., Hotchin, N., Lax, S. & Rumsby, M. Lysophosphatidic acid induces process retraction in CG-4 line oligodendrocytes and oligodendrocyte precursor cells but not in differentiated oligodendrocytes. J. Neurochem. 87, 947–957 (2003).
pubmed: 14622125
doi: 10.1046/j.1471-4159.2003.02056.x
Mitew, S. et al. Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol. 119, 567–577 (2010).
pubmed: 20198482
doi: 10.1007/s00401-010-0657-2
Barnes-Vélez, J. A., Aksoy Yasar, F. B. & Hu, J. Myelin lipid metabolism and its role in myelination and myelin maintenance. Innovation. 4, 100360 (2022).
pubmed: 36588745
pmcid: 9800635
Bouhrara, M. et al. Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement. 14, 998–1004 (2018).
pubmed: 29679574
pmcid: 6097903
doi: 10.1016/j.jalz.2018.03.007
Castilla-Ortega, E. et al. Aggravation of chronic stress effects on hippocampal neurogenesis and spatial memory in LPA
pubmed: 21980482
pmcid: 3183048
doi: 10.1371/journal.pone.0025522
Castilla-Ortega, E. et al. 1-Oleoyl lysophosphatidic acid: A new mediator of emotional behavior in rats. PLoS One 9, e85348 (2014).
pubmed: 24409327
pmcid: 3883702
doi: 10.1371/journal.pone.0085348
Yamada, M. et al. Lysophosphatidic acid induces anxiety-like behavior via its receptors in mice. J. Neural Transm. (Vienna) 122, 487–494 (2015).
pubmed: 25119538
doi: 10.1007/s00702-014-1289-9
Moreno-Fernández, R. D. et al. maLPA1-null mice as an endophenotype of anxious depression. Transl. Psychiatry 7, e1077 (2017).
pubmed: 28375206
pmcid: 5416683
doi: 10.1038/tp.2017.24
Li, Y. et al. Circular RNA expression profile of Alzheimer’s disease and its clinical significance as biomarkers for the disease risk and progression. Int. J. Biochem. Cell Biol. 123, 105747 (2020).
pubmed: 32315771
doi: 10.1016/j.biocel.2020.105747
Xiong, W. et al. CircLPAR1 promotes neuroinflammation and oxidative stress in APP/PS1 mice by inhibiting SIRT1/Nrf-2/HO-1 axis through destabilizing GDF-15 mRNA. Mol. Neurobiol. 60, 2236–2251 (2023).
pubmed: 36646968
doi: 10.1007/s12035-022-03177-8
Wu, L., Du, Q. & Wu, C. CircLPAR1/miR-212-3p/ZNF217 feedback loop promotes amyloid β-induced neuronal injury in Alzheimer’s Disease. Brain Res. 1770, 147622 (2021).
pubmed: 34403662
doi: 10.1016/j.brainres.2021.147622
Bhattarai, S. et al. The ATX-LPA axis regulates vascular permeability during cerebral ischemic-reperfusion. Int. J. Mol. Sci. 23, 4138 (2022).
pubmed: 35456953
pmcid: 9024554
doi: 10.3390/ijms23084138
Masago, K. et al. Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: Implication for hepatic encephalopathy. Biochem. Biophys. Res. Commun. 501, 1048–1054 (2018).
pubmed: 29778535
pmcid: 6108890
doi: 10.1016/j.bbrc.2018.05.106
Noel, R. L. et al. Natural aging and Alzheimer’s disease pathology increase susceptibility to focused ultrasound-induced blood-brain barrier opening. Sci. Rep. 13, 6757 (2023).
pubmed: 37185578
pmcid: 10130033
doi: 10.1038/s41598-023-30466-6
Rancoule, C. et al. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 56, 1394–1402 (2013).
pubmed: 23508306
doi: 10.1007/s00125-013-2891-3
Fayyaz, S. et al. Lysophosphatidic acid inhibits insulin signaling in primary rat hepatocytes via the LPA3 receptor subtype and is increased in obesity. Cell Physiol. Biochem. 43, 445–456 (2017).
pubmed: 28922661
doi: 10.1159/000480470
Lee, J. H. et al. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase. Biochim. Biophys. Acta Mol. Basis Dis. 1865, 1332–1340 (2019).
pubmed: 30763641
doi: 10.1016/j.bbadis.2019.02.001
Zhang, M. Z. et al. Lysophosphatidic acid receptor antagonism protects against diabetic nephropathy in a type 2 diabetic model. J. Am. Soc. Nephrol. 28, 3300–3311 (2017).
pubmed: 28739650
pmcid: 5661289
doi: 10.1681/ASN.2017010107
Li, H. Y., Oh, Y. S., Choi, J. W., Jung, J. Y. & Jun, H. S. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice. Kidney Int. 91, 1362–1373 (2017).
pubmed: 28111010
doi: 10.1016/j.kint.2016.11.010
Zhang, C. et al. Targeting lysophospholipid acid receptor 1 and ROCK kinases promotes antiviral innate immunity. Sci. Adv. 7, eabb5933 (2021).
pubmed: 34533996
pmcid: 8448453
doi: 10.1126/sciadv.abb5933
Khatiwada, S., Delhon, G., Chaulagain, S. & Rock, D. L. The novel ORFV protein ORFV113 activates LPA-p38 signaling. PLoS Pathog. 17, e1009971 (2021).
pubmed: 34614034
pmcid: 8523077
doi: 10.1371/journal.ppat.1009971
Nallur, G. Interaction of the SARS-COV2 envelope protein (E) with lysophosphatidic acid receptor 1 (LPAR1) and additional human proteins involved in inflammation, immunity, ADP ribosylation and vesicular transport. SSRN https://doi.org/10.2139/ssrn.3702607 (2020).
doi: 10.2139/ssrn.3702607
Reiken, S. et al. Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimers Dement. 18, 955–965 (2022).
pubmed: 35112786
pmcid: 9011576
doi: 10.1002/alz.12558
Ye, X. W. et al. Exploring the common pathogenesis of Alzheimer’s disease and type 2 diabetes mellitus via microarray data analysis. Front. Aging Neurosci. 15, 1071391 (2023).
pubmed: 36923118
pmcid: 10008874
doi: 10.3389/fnagi.2023.1071391
Leon-Abarca, J. A. et al. Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients. PLoS One 16, e0255144 (2021).
pubmed: 34343179
pmcid: 8330906
doi: 10.1371/journal.pone.0255144
Xia, X., Wang, Y. & Zheng, J. COVID-19 and Alzheimer’s disease: How one crisis worsens the other. Transl. Neurodegener. 10, 15 (2021).
pubmed: 33941272
pmcid: 8090526
doi: 10.1186/s40035-021-00237-2
Zhang, T. et al. Risk for newly diagnosed diabetes after COVID-19: A systematic review and meta-analysis. BMC Med. 20, 444 (2022).
pubmed: 36380329
pmcid: 9666960
doi: 10.1186/s12916-022-02656-y
Guo, W. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 36, e3319 (2020).
pubmed: 32233013
pmcid: 7228407
doi: 10.1002/dmrr.3319
Wang, L. et al. Association of COVID-19 with new-onset Alzheimer’s disease. J. Alzheimers Dis. 89, 411–414 (2022).
pubmed: 35912749
pmcid: 10361652
doi: 10.3233/JAD-220717
Vaz, E. S., Vassiliades, S. V., Giarolla, J., Polli, M. C. & Parise-Filho, R. Drug repositioning in the COVID-19 pandemic: Fundamentals, synthetic routes, and overview of clinical studies. Eur. J. Clin. Pharmacol. 79, 723–751 (2023).
pubmed: 37081137
pmcid: 10118228
doi: 10.1007/s00228-023-03486-4
Babalola, O. E. et al. A randomized controlled trial of ivermectin monotherapy versus hydroxychloroquine, ivermectin, and azithromycin combination therapy in COVID-19 patients in Nigeria. https://doi.org/10.21203/rs.3.rs-950352/v1 (2021).
Bramante, C. T. et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N. Engl. J. Med. 387, 599–610 (2022).
pubmed: 36070710
pmcid: 9945922
doi: 10.1056/NEJMoa2201662
Shi, Y., Chen, D., Ma, S., Xu, H. & Deng, L. Identification of potential biomarkers of depression and network pharmacology approach to investigate the mechanism of key genes and therapeutic traditional Chinese medicine in the treatment of depression. Evid. Based Complement. Alternat. Med. 2021, 2165632 (2021).
pubmed: 35003290
pmcid: 8741373
doi: 10.1155/2021/2165632
Xu, C. et al. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma. BMC Cancer 22, 264 (2022).
pubmed: 35279104
pmcid: 8918330
doi: 10.1186/s12885-022-09322-9
Suratanee, A. & Plaimas, K. DDA: A novel network-based scoring method to identify disease-disease associations. Bioinform. Biol. Insights 9, 175–186 (2015).
pubmed: 26673408
pmcid: 4674013
doi: 10.4137/BBI.S35237
Warde-Farley, D. et al. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 38, W214-20. https://doi.org/10.1093/nar/gkq537 (2010).
doi: 10.1093/nar/gkq537
pubmed: 20576703
pmcid: 2896186
Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607–D613 (2019).
pubmed: 30476243
doi: 10.1093/nar/gky1131
Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. The Phyre2 web portal for protein modeling, prediction and analysis. Nat. Protoc. 10, 845–858 (2015).
pubmed: 25950237
pmcid: 5298202
doi: 10.1038/nprot.2015.053
Eswar, N. et al. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 31, 3375–3380 (2003).
pubmed: 12824331
pmcid: 168950
doi: 10.1093/nar/gkg543
Muhammed, M. T. & Aki-Yalcin, E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem. Biol. Drug Des. 93, 12–20 (2019).
pubmed: 30187647
doi: 10.1111/cbdd.13388
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. PROCHECK—A program to check the stereochemical quality of protein structures. J. Appl. Cryst. 26, 283–291 (1993).
doi: 10.1107/S0021889892009944
Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477–486 (1996).
pubmed: 9008363
doi: 10.1007/BF00228148
Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714–2723 (1997).
pubmed: 9504803
doi: 10.1002/elps.1150181505
Yan, Y., Tao, H., He, J. & Huang, S. Y. The HDOCK server for integrated protein–protein docking. Nat. Protoc. 15, 1829–52 (2020).
pubmed: 32269383
doi: 10.1038/s41596-020-0312-x
Wang, R., Fang, X., Lu, Y. & Wang, S. HawkDock: A web server to predict and analyze the binding protein hotspots and regulatory hotspots. Bioinformatics 36, 1762–1764 (2020).
Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221–234 (2013).
pubmed: 23579614
doi: 10.1007/s10822-013-9644-8
Agu, P. C. et al. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci. Rep. 13(1), 13398 (2023).
pubmed: 37592012
pmcid: 10435576
doi: 10.1038/s41598-023-40160-2
Laskowski, R. A. PDBsum 1: A standalone program for generating PDBsum analyses. Protein Sci. 31, e4473 (2022).
pubmed: 36251626
pmcid: 9667822
doi: 10.1002/pro.4473
Wiehe, K., Peterson, M. W., Pierce, B., Mintseris, J. & Weng, Z. Protein-protein docking: Overview and performance analysis. Methods Mol. Biol. 413, 283–314 (2008).
pubmed: 18075170
Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement. 8, e12295 (2022).
doi: 10.1002/trc2.12295
Feingold, K.R. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Feingold, K.R. et al. (Eds). https://www.ncbi.nlm.nih.gov/books/NBK279141/ (2022).
Halgren, T. A. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J. Comput. Chem. 17, 490–519 (1996).
doi: 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
Baxendale, I. R., Hayward, J. J., Ley, S. V. & Tranmer, G. K. Pharmaceutical strategy and innovation: An academics perspective. ChemMedChem. 2, 768–788 (2007).
pubmed: 17458911
doi: 10.1002/cmdc.200700008
McConkey, B. J., Sobolev, V. & Edelman, M. The performance of current methods in ligand-protein docking. Curr. Sci. 83, 845–855 (2002).
Meng, X. Y., Zhang, H. X., Mezei, M. & Cui, M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 7, 146–157 (2011).
pubmed: 21534921
pmcid: 3151162
doi: 10.2174/157340911795677602
Wong, C. H., Siah, K. Z. & Lo, A. W. Estimation of clinical trial success rates and related parameters. Biostatistics 20, 273–286 (2019).
pubmed: 29394327
doi: 10.1093/biostatistics/kxx069
Brimson, J. M. et al. Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy. Expert Opin. Ther. Targets 25, 435–449 (2021).
pubmed: 34236922
doi: 10.1080/14728222.2021.1952987
Roncon, L., Zuin, M., Rigatelli, G. & Zuliani, G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J. Clin. Virol. 127, 104354 (2020).
pubmed: 32305882
pmcid: 7195018
doi: 10.1016/j.jcv.2020.104354
Tan, L. et al. Neurological implications of COVID-19: A review of the science and clinical guidance. BMJ Neurol. Open 2, e000101 (2020).
pubmed: 33681805
pmcid: 7871721
doi: 10.1136/bmjno-2020-000101
Huang, C. C. et al. Diabetes mellitus and the risk of Alzheimer’s disease: A nationwide population-based study. PLoS One 9, e87095 (2014).
pubmed: 24489845
pmcid: 3906115
doi: 10.1371/journal.pone.0087095
Biessels, G. J. & Kappelle, L. J. Increased risk of Alzheimer’s disease in Type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem. Soc. Trans. 33, 1041–1044 (2005).
pubmed: 16246041
doi: 10.1042/BST0331041
Kouhpayeh, H. R. et al. Association between angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1) polymorphisms and COVID-19 infection in the southeast of Iran: A preliminary case-control study. Transl. Med. Commun. 6, 26 (2021).
pubmed: 34805533
pmcid: 8596349
doi: 10.1186/s41231-021-00106-0
D’Alessandro, A. et al. Serum proteomics in COVID-19 patients: Altered coagulation and complement status as a function of IL-6 level. J. Proteome Res. 19, 4417–4427 (2020).
pubmed: 32786691
pmcid: 7640953
doi: 10.1021/acs.jproteome.0c00365
Goldstein, B., Speth, R. C. & Trivedi, M. Renin-angiotensin system gene expression and neurodegenerative diseases. J. Renin Angiotensin Aldosterone Syst. 17, 1470320316666750 (2016).
pubmed: 27613758
pmcid: 5843881
doi: 10.1177/1470320316666750
Muenchhoff, J. et al. Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease. Sci. Rep. 6, 29078 (2016).
pubmed: 27381087
pmcid: 4933916
doi: 10.1038/srep29078
Ribeiro-Oliveira, A. Jr. et al. The renin-angiotensin system and diabetes: an update. Vasc. Health Risk Manag. 4, 787–803 (2008).
pubmed: 19065996
pmcid: 2597759
doi: 10.2147/VHRM.S1905
Xiao, H. et al. Comprehensive proteomic profiling of aqueous humor proteins in proliferative diabetic retinopathy. Transl. Vis. Sci. Technol. 10, 3 (2021).
pubmed: 34111250
pmcid: 8107506
doi: 10.1167/tvst.10.6.3
Sodhi, A., Montaner, S. & Gutkind, J. Viral hijacking of G-protein-coupled-receptor signalling networks. Nat. Rev. Mol. Cell Biol. 5, 998–1012 (2004).
pubmed: 15573137
doi: 10.1038/nrm1529
Edmiston, E. A., Bej, T. A., Wilson, B., Jump, R. L. P. & Phillips, J. A. Donepezil-associated survival benefits among Alzheimer’s disease patients are retained but not enhanced during COVID-19 infections. Ther. Adv. Infect. Dis. 10, 20499361231174290 (2023).
pubmed: 37234745
pmcid: 10203853
Mansoor, A. F. A. & Raghif, A. R. A. Attenuated effects of rivastigmine in induced cytokine storm in mice. J. Emerg. Med. Trauma Acute Care 2022, 12 (2022).
Nguyen, N. N. et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis. Metabolism 131, 155196 (2022).
pubmed: 35367460
pmcid: 8970613
doi: 10.1016/j.metabol.2022.155196
Choudhary, V., Gupta, A., Sharma, R. & Parmar, H. S. Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. J. Proteins Proteom. 12, 257–270 (2021).
pubmed: 34539131
pmcid: 8440732
doi: 10.1007/s42485-021-00074-x
Luedemann, M. et al. Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. Comput. Struct. Biotechnol. J. 20, 799–811 (2022).
pubmed: 35126884
pmcid: 8800171
doi: 10.1016/j.csbj.2022.01.024
Mulgaonkar, N. et al. Montelukast and telmisartan as inhibitors of SARS-CoV-2 omicron variant. Pharmaceutics 15, 1891 (2023).
pubmed: 37514075
pmcid: 10385313
doi: 10.3390/pharmaceutics15071891
Balan, I. et al. Neurosteroid allopregnanolone (3α,5α-THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors. Transl. Psychiatry 11, 145 (2021).
pubmed: 33637705
pmcid: 7909379
doi: 10.1038/s41398-021-01266-1
Barge, S., Jade, D., Gosavi, G., Talukdar, N. C. & Borah, J. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2). Eur. J. Pharm. Sci. 162, 105820 (2021).
pubmed: 33775827
pmcid: 7997164
doi: 10.1016/j.ejps.2021.105820
Singh, R. et al. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: A multiple target approach. In Silico Pharmacol. 9, 27 (2021).
pubmed: 33842191
pmcid: 8019482
doi: 10.1007/s40203-021-00089-8
Hoda, M. R., Kramer, M. W., Merseburger, A. S. & Cronauer, M. V. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin. Pharmacother. 18, 105–113 (2017).
pubmed: 27826989
doi: 10.1080/14656566.2016.1258058
Bhowmick, N. A. et al. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr. Relat. Cancer 27, R281–R292 (2020).
pubmed: 32508311
pmcid: 7546583
doi: 10.1530/ERC-20-0165